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T-cell lymphomas include diverse malignancies. They are rare, some have low survival 
rates and they lack curative therapies. The aim of this work was to assess whether 
employing the TLR7 agonist imiquimod and the T-cell costimulatory molecule CD40 or 
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the combination of both as adjuvants of a cell lysate vaccine could enhance the antitumor 
immune response using a murine T-cell lymphoma model.  
Immunization with LBC-lysate and imiquimod protected almost all vaccinated animals. A 
specific humoral and a Th1-type cellular immunity were induced in mice that rejected the 
lymphoma, characterized by an elevated number of CD4+T-cells and secretion of IFN-γ, 
locally and systemically. In contrast, CD40 alone or in combination with imiquimod did not 
improve the protective response obtained with LBC-lysate and imiquimod. Systemic 
administration of imiquimod proved to have high potential to serve as a vaccine adjuvant 
for the treatment of T-cell lymphomas and was effective in this immunotherapy model. 
 




T-cell lymphomas are a group of diverse histologic subtypes of non-Hodgkin neoplasms 
that represent 12 to 15% of all lymphoid tumors. They include very heterogeneous 
diseases such as T-lymphoblastic lymphoma/leukemia, angioimmunoblastic T-cell 
lymphoma, follicular T-cell lymphoma, anaplastic large-cell lymphoma, adult T-cell 
leukemia/lymphoma, extranodal lymphomas, and cutaneous T-cell lymphomas to name a 
few [1]. They can occur in children or adults, they can also localize systemically or in 
skin and can be fast or slow-growing depending on the type. These various factors will 
determine their aggressiveness. The aggressive types, even though they are infrequent, 
have a 5-year progression-free survival rate of only 31%–36%, which varies according to 












standard treatment CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) 
or similar schemes, remission is achieved in only half of patients. Some alternative 
therapies involve approaches of intensive chemotherapy or combined chemotherapy with 
autologous stem cell transplantation. However, they failed to improve response rates or 
showed limited benefits [2]. One reason for the poor outcome for these patients is the 
lack of new treatment strategies to improve survival, so immunotherapy using tumor 
vaccines appears to be a promising therapy. 
 
Immunotherapies based on tumor cell lysates have proved to be effective vaccines in 
humans [3] [4]. Immunological adjuvancy is a necessary tool in the field of tumor 
vaccines to enhance immunomodulatory pathways leading to functional response. To 
initiate an antitumor immune response and to generate effector and memory T-cells, 
APC
2
 must undergo activation and maturation through recognition of danger signals. In 
this sense, direct stimulation of APC mediated by adjuvants would modulate the type of 
immune response elicited. One strategy to achieve this stimulation is through the 
interaction of antigens with pattern-recognition receptors such as TLR
3
 present in the 
APC. 
 
To date, many specific agonists for TLR have been identified. However, whether these 
ligands induce an effective therapeutic antitumor response remains to be determined. A 
member of the imidazoquinoline family called imiquimod is a TLR7 agonist. Imiquimod 
is a nucleoside analogue that mimics the immune response to viral single-stranded RNA. 
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TLR7 stimulation increases the production and secretion of proinflammatory cytokines, 
chemokines and adhesion molecules through activation of the transcription factor NF-κB 
[5]. Imiquimod induces, recruitment and transformation of plasmacytoid DC
4
, into 
cytotoxic plasmacytoid DC [6], stimulating the expression of costimulatory molecules. It 
also promotes a Th1-cellular response and the suppression of the Th2-pathway, enhances 
the activation of CD8+ T cytotoxic cells and macrophages, improves NK
5
 cell activity, 
and induces proliferation and differentiation of B-cells [7]. As a topical formulation, 
imiquimod has been demonstrated to have an antiviral effect and it has been approved by 
US Food and Drug Administration (FDA) for the treatment of external genital and 
perianal warts, superficial basal cell carcinoma, and actinic keratosis [7]. Furthermore, 
antiangiogenic [8] and proapoptotic effects on malignant keratinocytes, melanoma cells 
[9] [10], as well as T-lymphoma cells, both murine and human [11] have been 
demonstrated for this compound. 
 
CD40 is one of the most important TCR
6
 costimulatory molecules, which binds to CD154 
(CD40L) found in activated T-cells, B-cells, NK, DC, monocytes, and granulocytes 
among others cells. The direct binding of CD40 to CD40L can regulate DC functions and 
T-cell activation, and both T-cell and DC signaling. CD40 triggering can also induce 
innate immune cells activation leading to antitumor mechanisms. An effective antitumor 
response must also be capable of stimulating the expression of adhesion and 
costimulatory molecules. T-cell activation requires two different signals from APC. The 
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first one involves antigen presentation to the TCR in the context of MHC and the second 
signal needs the engagement of each costimulatory molecule with its ligand to avoid 
anergy. In previous works we have demonstrated that LBC tumor cells transfected with 
CD40 (LBC.CD40)
7
 induced a significant increase in specific cytotoxic T-cell activity, 
IFN- secretion, and significant tumor rejection after LBC.CD40 inoculation [12]. CD40 
has also been used as a molecular adjuvant to enhance weak immunogenic vaccines, as is 
the case of DNA vaccines. CD40-CD40L interaction has been shown to enhance cellular 
and humoral immune responses to vaccination against HIV, hepatitis C, H5N1 influenza, 
and foot-and-mouth disease virus [13] [14] [15] [16]. 
 
The aim of this study was to determine whether the use of imiquimod and CD40 (two 
adjuvants directed against two different immunological targets) could enhance the 
antitumor immune response elicited by a cell lysate vaccine in order to achieve tumor 
rejection in a murine model of T-cell lymphoma. 
 
2. MATERIAL AND METHODS 
 
2.1 Cell line: The syngeneic BALB/c T-cell lymphoma cell line, LBC (H-2
d
) was 
maintained in RPMI 1640 (Gibco™, Invitrogen, CA, USA) supplemented with 10% heat-
inactivated fetal bovine serum (Invitrogen, CA, USA), 2 mM glutamine, 25 mM HEPES 
buffer, 100 IU/ml penicillin, 100 μg/ml streptomycin, and 0.05 mM 2-mercaptoethanol, as 
previously described [17]. LBC.CD40 cells were established from LBC cells after 
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transfection with pcD-SRαCD40 as previously described [12]. CD40 expression on 
LBC.CD40 was evaluated by flow cytometry before using them in the experiments. 
 
2.2 Mice: Six to ten-weeks old female immunocompetent BALB/c mice were purchased 
from the School of Veterinary Sciences, Universidad de Buenos Aires (Buenos Aires, 
Argentina). Animals were fed on Cargill pellets and water ad libitum. All procedures 
involving animals followed guidelines of Institutional Animal Care and Use Committee 
(CICUAL) of University of Buenos Aires Medical School. 
 
2.3 Freeze-thaw lysate: LBC and LBC.CD40 cells were harvested and washed twice with 
PBS. Cells were then suspended in PBS (2x10
6 
cells/ml) and lysed by means of 3 to 4 
cycles of freezing at -70°C and thawing at 37°C, vortexing after each round. Total cell 
death was confirmed by trypan blue dye exclusion. Protein concentration was determined 




 were then aliquoted and stored at -
70°C until used.  
 
2.4 Reagents: Imiquimod (3M Pharmaceuticals R-837) was dissolved in sterile acidic 
deionized distilled water (pH 2.5) at a concentration of 1 mg/ml [18], sterilized by 0.22 
µm membrane filtration and diluted at working concentration in PBS. Corresponding 
control was identically prepared with the same volume of acidic deionized distilled water 
(pH 2.5) and PBS, but without imiquimod. The final pH value of imiquimod solution and 
control solutions used to inject the mice was always adjusted between 6.5 and 7.  
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2.5 Immunization and tumor challenge: Mice were randomly divided into six groups 
and vaccinated i.p.
10
 once a week for 2 weeks. For each injection, each group of mice 
received a final treatment of one of the following: 0.5 ml of 100 µg of LBC-lys proteins; 
100 µg of LBC-lys proteins mixed with 100 μg of imiquimod; 100 µg of LBC.CD40-lys 
proteins; 100 µg of LBC.CD40-lys proteins mixed with 100 μg of imiquimod; 100 μg of 
imiquimod, or PBS alone as controls. Seven days after the last immunization, animals 
were challenged with 1x10
6 
LBC tumor cells i.p, a dose that has been determined to cause 
90-100% lethality at 21±4 days after injection. Mice survival was monitored daily and the 
rate of mortality and survival were recorded. It has previously been determined in our 
laboratory that 100 μg of imiquimod is the optimum dose to be used as adjuvant without 
any side effect in immunized mice.  
 
To evaluate whether the mice had developed a memory response in vivo, the animals 
previously vaccinated that had rejected the first tumor challenge were re-challenged 80 
days after the first tumor injection with 1x10
6 
LBC tumor cells i.p. The survival time of 
the animals was recorded daily. Survival curves from these treated mice were compared 
with survival curves from naïve mice of the same age inoculated i.p. with 1x10
6 
LBC 
cells at the same time. 
 
2.6 In vitro specific T-cell amplification and T-cell Cytotoxicity assay: Splenocytes 
(5x10
6
/ml) from naïve and immunized mice that rejected LBC lymphoma were harvested 















and stimulated in vitro with 1x10
5
/ml irradiated LBC cells (3000 cGy) for 7 to 10 days at 
37°C in 5% CO2. Recombinant IL-2 (33U/ml) (eBioscience, CA, USA) was added on 
days 2 and 5 of culture. Activated splenocytes were washed, counted and used as effector 
cells to analyze cytotoxic-induced DNA fragmentation measured by the Jam test [19]. 
Briefly, LBC cells were labeled with 5μCi/ml of [
3
H] thymidine (NEN™, MA, USA) 





LBC cells were cultured with effector cells for 4 h at different effector: target ratios 
(90:1, 60:1 and 30:1) in a round-bottom 96-well plate at 37°C in 5% CO2. Cells were 
harvested on a PHD™ Sample Harvester (Brandel, MD, USA) and radioactivity was 
measured in a liquid scintillation beta counter (Tri-Carb 2800TR, Perkin Elmer). Induced 
and spontaneous releases were determined by incubating LBC target cells with effector 
cells or with culture medium alone, respectively. The percentage of specific lysis was 
calculated as [(spontaneous release – experimental release)/ spontaneous release] x 100. 
 
2.7 Immunofluorescence cell staining and flow cytometric analysis: Cells isolated from 
spleen or the peritoneal cavity of mice that had rejected the tumor, or splenocytes 
stimulated in vitro (as described above) were stained with different monoclonal 
antibodies and analyzed by flow cytometry. Cells from naïve mice were used as control. 
Briefly, 5x10
5
 cells were stained with specific FITC-conjugated anti-CD4 (L3T4) (clone 
GK1.5), FITC-conjugated anti-mouse/human CD45R (B220) (clone RA3-6B2), or PE-
conjugated anti-mouse CD8b (Ly-3) (clone eBioH35-17.2) (eBioscience, CA, USA) in 
FACS buffer (PBS, 5% fetal bovine serum and 0.1% NaN3) for 30 min on ice. Isotype-












and fixed with 1% paraformaldehyde for 20 min. Stained cells were analyzed on a 
FACSCalibur flow cytometer (Becton Dickinson, CA, USA). 
 
2.8 Measurement of Cytokines by ELISA: Splenocytes (5x10
6
/ml) or cells from the 
peritoneal cavity (2.5x10
6
/ml) obtained from naïve mice and from vaccinated mice that 
had rejected the tumor were stimulated in culture with 1x10
5
/ml irradiated LBC cells 
(3000 cGy) for 48 h and supernatants were then collected. Concentrations of IFN-γ and 
IL-4 were quantified using specific ELISA kits (eBioscience, CA, USA).   
 
2.9 Dot blot: Sera were collected from naïve and immunized mice that had rejected the 
tumor one day before sacrifice, and the presence of specific anti-LBC antibodies was 
evaluated by dot blot using LBC cells as antigens. Briefly, 1x10
4
 LBC cells/2 µl PBS 
were loaded in duplicate onto strips of a nitrocellulose membrane (Hybond™-ECL™ 
Amersham Bioscience) and allowed to adsorb completely (about 3-5 min). Membrane 
strips were placed in 35 mm culture dishes and blocked overnight at 4°C in blocking 
buffer (10% non-fat dry milk in TTBS solution: 100 mM Tris-HCl pH 7.5, 0.9% NaCl 
and 0.1% Tween 20). After washing with TTBS 3-4 times, strips were incubated 
overnight at 4°C with serial dilutions of each serum. Membranes were then washed and 
incubated with a goat anti-mouse IgG-HRP antiserum (1/2000) (eBioscience, CA, USA) 
for 1 h at room temperature and revealed using SuperSignal™ West Pico 
Chemiluminescent Substrate (Thermo Fisher Scientific, Rockford, IL, USA). The 














2.10 Statistical analysis: Survival fractions were calculated using the product-limit 
Kaplan-Meier method and differences between treatments were evaluated by log-rank 
statistics. Data obtained by flow cytometry were analyzed using CellQuest (Becton 
Dickinson, CA, USA) or Win.MDI (Windows Multiple Document Interface) Flow 
Cytometry Applications. For statistical comparisons, a one-way ANOVA with Tukey’s 
post-test was performed using GraphPad Prism version 5.00 for Windows (GraphPad 




3.1 Tumor cell lysate vaccination using imiquimod as an adjuvant enhanced the 
protection from tumor growth  
 
To evaluate the efficacy of tumor lysate vaccination using either imiquimod or CD40 as 
adjuvants, BALB/c mice were injected i.p. with LBC-lys, LBC.CD40-lys, LBC-lys + 
imiquimod or the combination LBC.CD40-lys + imiquimod twice every 7 days. The third 
week, the mice were challenged i.p. with 1x10
6
 viable LBC tumor cells, and survival was 
recorded daily. As shown in Fig.1 A, all vaccines prolonged survival as compared to 
control non-immunized animals and to mice receiving only imiquimod (p<0.001). 
Imiquimod used as an adjuvant in LBC-lys vaccine, markedly improved survival when 
compared with mice immunized with LBC-lys without adjuvant (p<0.05) and with mice 
that received LBC.CD40-lys (p<0.05). However, a combination of both adjuvants, 
imiquimod and CD40, did not improve survival compared to the use of imiquimod as the 












vaccine protected only 46.7 ± 13% of mice and only 60 ± 13% of the immunized with 
LBC.CD40-lys survived, 93.3 ± 6% of animals immunized with LBC-lys + imiquimod 
remained free of any observable tumor at the end of the study (60 days after tumor cell 
injection). Surprisingly, the presence of CD40 did not improve the effect of imiquimod. 
No difference was observed when combining LBC.CD40-lys + imiquimod since 80 ± 
13% of mice were protected from tumor challenge. We studied protein expression of 
CD40 molecule in lysates of LBC cells transfected with pcD-SRCD40 plasmid. 
Western blotting indicated a protein of the expected mass (~ 45 kDa) as shown by SDS-
PAGE analyses under reducing conditions (data not shown), confirming that CD40 
protein expression was present in the lysate vaccine. However, no clinical effect was 
observed with CD40 used as an adjuvant of the immunization. All mice that have 
survived the tumor challenge were still alive after one year from the vaccination. 
 
To further investigate if LBC-lys + imiquimod could induce a long-term antitumor 
immunity against a second parent tumor challenge, mice that had survived over 80 days 
after tumor cell injection and naïve mice that were used as control were inoculated with 
LBC cells i.p. Almost all mice that had been vaccinated and had rejected the first tumor 
challenge survived the lethal tumor re-challenge over 120 days, whereas 100% of mice in 
the control group died (Figure 1 B). 
 
3.2 Tumor cell lysate vaccination using imiquimod as an adjuvant induced a Th1-













In order to investigate the immunomodulatory effect of imiquimod on LBC-lys vaccine in 
mice that had rejected the tumor, 47 days after the last booster we analyzed the immune 
response induced locally (in the peritoneum) and systemically (in the spleen). We first 
evaluated changes in lymphocyte subpopulations by flow cytometry. The addition of 
imiquimod to LBC-lys significantly induced an increase in the absolute number of CD4+ 
T-cells (p<0.05) in the peritoneum in comparison with the group immunized with LBC-
lys (Figure 2 A). Mice inoculated with LBC-lys + imiquimod developed splenomegaly 
with an increase in the absolute number of CD4+ T-cells (p<0.05) in spleen (Figure 2 B). 
Moreover, the percentage of CD4+ T-cells primed in vivo was markedly amplified after 
co-culture in vitro splenocytes from immunized mice with irradiated LBC cells during 7 
days, (Figure 2 C). A significant difference was observed in specific CD4+ T-cells 
obtained from mice that received LBC-lys + imiquimod that were expanded in vitro 
(p<0.05) (33.5 ± 3.5%) compared to those animals inoculated with LBC-lys (21.5 ± 
2.1%), to unimmunized mice (PBS group) (19.5 ± 2.1%) and to mice that received 
imiquimod alone (21 ± 2.8%). On the contrary, the percentage and absolute number of 
CD8+ T-cells, as well as B220+ cells (B-cells), did not change significantly in the 
peritoneum or in the spleen. 
 
To further elucidate whether the vaccine elicited a Th1 or Th2-profile, the levels of IFN-γ 
and IL-4 were determined. The levels of IFN-γ in the supernatant of splenocytes obtained 
from mice immunized with LBC-lys + imiquimod that had rejected the tumor were higher 
than those obtained from mice immunized with LBC-lys, and from those obtained from 
naïve mice (p<0.001, Figure 3 A). Similar results were found when the local response 












from mice inoculated with LBC-lys + imiquimod were higher than those found in either 
the supernatant of peritoneal cells obtained from mice immunized with LBC-lys alone; 
from naïve mice, or from unimmunized animals that had rejected tumor challenge 
(p<0.001, Figure 3 B). On the other hand, the vaccination did not elicit a higher 
production of IL-4 in any of the groups (Fig. 3 C). These data suggest that the vaccines 
induced a Th1-type pattern of cell-mediated immune response in the immunized mice 
that could have promoted the antitumor activity. 
 
To determine whether vaccines elicited a specific cytolytic response, an in vitro cytotoxic 
assay was performed. From the three-different effector: target ratios evaluated (90:1, 60:1 
and 30:1), the 90:1 ratio was the one that provided the best responses and is the one 
depicted in Fig. 3D. Surprisingly, the cell cytotoxicity induced against LBC in BALB/c 
mice inoculated with LBC-lys + imiquimod (15.7 ± 1.7%) was not higher than that 
obtained from mice vaccinated with the LBC-lys alone (17.7 ± 1.7%), even though there 
was a significant increase with respect to the naïve control (7 ± 1.8 %) (p<0.001).These 
results are in accordance with the fact that the number on CD8+ T-cells did not differ 
among the groups. 
 
Thus, it can be concluded that the use of imiquimod as an adjuvant in LBC-lys vaccine 
increased the cellularity in spleen and peritoneum. This phenomenon could be attributed 
to a CD4+ T-cell expansion and to the high frequency of specific CD4+ T-cells in spleen. 
Finally, to assess the humoral response, antibodies against LBC tumor cells were detected 












imiquimod to LBC-lys vaccine generated a slightly higher humoral response (12800 




In this work, we demonstrated that imiquimod alone significantly enhanced the 
immunogenicity of the LBC cell lysate vaccine against the T-cell lymphoma, since it 
allowed nearly a 40% increase in the mice survival rate, achieving almost a complete tumor 
rejection for the overall group. Our results are in agreement with previous studies in which 
imiquimod proved to be efficient as adjuvant, exhibiting antitumor effects in a melanoma 
model of therapeutic and prophylactic vaccines [20], boosting immune response of an anti-
melanoma peptide-vaccine [21] or reducing the incidence of a mammary tumor in 
comparison with the vaccination alone [22]. On the other hand, costimulatory molecules 
used as adjuvants have proved effective to eradicate cervical and lung tumors, even more 
effectively than some TLR agonists, as Sharma et al, demonstrated previously for a soluble 
form of 4-1BBL with a peptide vaccine [23]. However, in our model of lysate vaccine, the 
use of CD40 molecule as part of the lysate of LBC transfected cells, did not prolong the life 
of the animals more than the vaccine alone did. Furthermore, its combination with 
imiquimod did not synergize the effect of either of the two. Although the reasons for this 
are not clear, we hypothesized that the protein was functional in fact but the amount 
expressed of CD40 might have been insufficient to boost the immune response elicited by 













The choice of a vaccine to treat a T-cell lymphoma was based on the fact that it could 
induce an adaptive immune response to tumor antigens that are easily available to immune 
system and the possibility to overcome the immunosuppressive tumor microenvironment 
due to the immunomodulation of the adjuvants. Tumor-cell lysate vaccines have advantages 
over other vaccines, such as those based on purified or recombinant antigens which allow 
DC to elicit an effective polyclonal immune response in patients with cancer providing a 
high number of immunogenic CD4+ and CD8+ T tumor epitopes. The need for this 
immunotherapy lies in that some T-cell lymphomas can be quite aggressive, such as the one 
presented here, and have poor survival outcome. In this sense, imiquimod was chosen as 
adjuvant due to its capacity to act as a TLR7 agonist, activating transcription factors (like 
NF-κB) that induce expression of proinflammatory cytokines and chemokines. Thus, the 
antitumor effect of imiquimod would be mediated by improving the viability and the 
activation of DC, which modulates the immune response by the secretion of IFN-α, TNF-α, 
IL-2, IL-8, or IL-12, among others, that in turn stimulate T lymphocytes, NK cells and 
promote Th1-type immunity [7]. Furthermore, we chose the TCR-costimulatory molecule 
CD40 as adjuvant to stimulate activated specific helper T-cells, protecting them from 
apoptosis and consequently, increasing the positive signal on APC. Interaction between 
helper T-cells and APC is essential to enhance antigen presentation and to increase 
expression of costimulatory molecules on APC, in order to activate CD8+ T-cells and 
generate cytotoxic memory T-cells [24] thereby inducing an effective antitumor immune 
response. In our previous studies, the presence of CD40 lengthened survival of LBC tumor-
bearing mice [12] and induced tumor rejection in the majority of the immunized mice with 
an irradiated whole tumor cells vaccine transfected with CD40 as adjuvant (manuscript in 












as effective to stimulate an antitumor immune response as the intact tumor cells transfected 
with CD40 and irradiated. 
 
In this study, the effect of imiquimod was stronger than that of the molecular adjuvant 
CD40. For this reason, the systemic and local immune response was assessed only in mice 
that received the LBC-lys plus imiquimod vaccine. The immunological profile elicited by 
this vaccine in our model was essentially of the Th1-type, as we detected IFN-γ but not IL-
4 in the supernatant obtained from splenocytes and peritoneal cells derived from mice 
immunized and co-cultured with irradiated LBC cells. An accumulation of CD4+ T-cells in 
the peritoneum and specific CD4 + T-cells in the spleen of these animals was also 
observed, indicative of a local and systemic activation of the immune system. Notably, this 
vaccine induced a long-lasting immune response keeping the mice free of tumor over one 
year. A contribution of the humoral arm in the antineoplastic response could not be ruled 
out, as we demonstrated the induction of significantly high titers of serum anti-LBC 
antibodies. It is also noteworthy that in our in vivo experiments, no signs of clinical toxicity 
were observed in mice inoculated with imiquimod alone, those vaccinated with LBC-lys, or 
those that received a combination of LBC.CD40-lys and imiquimod. This fact reinforces 
the idea that imiquimod proved to be safe, administered by systemic route. A vaccine that 
included imiquimod that induced Th1 polarized response featuring an increase in IFN-γ has 
been reported elsewhere previously [25]. In this case, the response has also been found to 
be accompanied by high titers of antibodies [22]. Unexpectedly, in the present study, the 
LBC-lys + imiquimod vaccination did not increase the CD8+ T-cell numbers and their 
cytotoxic activity in vitro. These results are consistent with a previous report where 












secretion of IFN-γ, but did not increase CD8+ T-cell response [26]. Furthermore, the 
essential requirement of CD4+ T-cells and IFN-γ production, rather than the CD8+ T-cells 
in rejection of tumors that do not express MHC II molecules, as the LBC lymphoma, has 
been described before [27]. The induction of a CD4+ T-cell response of the Th1-type, 
characterized mainly by the secretion of IFN-γ, is important to achieve an optimal 
antitumor response. IFN-γ is known to have a cytostatic/cytotoxic effect on tumor cells [28] 
to induce tumor dormancy [29], and to up-regulate MHC molecules as well as to alter the 
antigen-processing machinery [30]. IFN-γ can also have immunomodulatory properties 
through the recruitment of innate immune cells, the activation of macrophages and the 
induction of chemokines secretion which recruit specific effector cells to the site of 
inflammation. IFN-γ also regulates the activation, differentiation, and homeostasis of T-
cells; it promotes Th1-profile [31], and induces the secretion of antiangiogenic chemokines 
by DC [27]. Together, these biological properties of IFN-γ contribute to tumor rejection. 
The CD4+ T-cells also provide help to generate and maintain the specific CD8+ T-cell 
antitumor response [32] [33] and a tumor-specific memory CD8 T-cell population [24]. 
 
Considering these results, we hypothesize that imiquimod induces the activation of 
plasmacytoid and myeloid DC loaded with LBC antigens or even stimulates M1-
macrophages through TLR7. These cells would promote a proinflammatory 
microenvironment through the secretion of chemokines and cytokines such as IL-12, IL-6, 
IL-8, TNF-α, IFN-γ, IFN-α/β, G-CSF, or GM-CSF, among others. This fact would favor a 
CD4+ T differentiation towards a Th1-profile; T γ/δ, NK, and CD8+ T-cells activation and 
proliferation and differentiation of B-cells. These changes appear to trigger an effective 












only an increment of CD4+ T-cells associated with a local IFN-γ secretion in the 
peritoneum. However, it can be hypothesized that these mechanisms are also activated 
systemically, since the same results were obtained with splenocytes and in addition a 
humoral immune response was elicited as we found serum anti-LBC antibodies. Likewise, 
imiquimod might be exerting its effects through other mechanisms, such as the interaction 
with the adenosine receptor, which is known to be up regulated during inflammatory 
processes [34]. 
 
Our results demonstrate that imiquimod improved the antineoplastic effect of a lysate tumor 
vaccine as an adjuvant. These results also suggest that imiquimod acts as an APC 
stimulator. Nowadays, the usefulness of imiquimod in the treatment of skin tumors is being 
widely investigated; however, case reports about its efficacy in remission of clinical lesions 
in the treatment of lymphomas is scanty [35] [36] [37] [38] [39] [40]. Besides, the effect of 
imiquimod as an adjuvant for tumor vaccines, is already being tested in phase I clinical 
trials with patients with glioma [41] [42] and melanoma [26], but only as a topical 
formulation. While most studies report the topical administration of imiquimod, we 
demonstrated that it was also effective as a systemic application to treat lymphoma and 
consequently, it is not restricted to skin malignancies. The use of imiquimod as an adjuvant 
in tumor vaccines may also contribute with additional benefits. Previous works carried out 
in our laboratory have demonstrated that this compound has an anti-proliferative effect in 
vitro on LBC cells through a dose-dependent induction of apoptosis, at concentrations 
between 1 and 100 µg/ml (Di Sciullo and Mongini personal communication) as it has been 
reported to have an oncolytic effect on other tumor cells [9] [10] [11]. Furthermore, 












reported by others [43] [44]. The results presented herein could have clinical implications 
for the treatment of T-cell lymphomas since no reports were found using this type of tumor 
lysate vaccine. However, further studies evaluating other immunological pathways 
involved in the response, including regulatory T-cells or myeloid-derived suppressor cells, 
are required. The lack of targeting negative regulatory receptors on T-cells (PD-1, TIM-3, 
LAGE-3) and/or immune inhibitory cell populations in the tumor microenvironment could 
be a limitation of the tumor lysate vaccine with imiquimod. In this regard, the addition of 
another immunotherapy that modulates these immune checkpoint mechanisms could be 
necessary in order to overcome immune dysfunctions frequently present in cancer patients.  
 
Imiquimod demonstrated to be a safe drug in this model when administered by the systemic 
route. Although it has been approved by the FD  only for topical use, it has been found to 
be effective when administered orally [45], but toxic at high doses [46]. In this sense, the 
administration of imiquimod as an adjuvant in low doses alone, or in combination with 





To sum up, we investigated the antitumor effect of a tumor vaccine that included 
imiquimod and CD40 molecule as adjuvants and evaluated their effectiveness in a murine 
T-cell lymphoma model. We have found that imiquimod administered alone significantly 
enhanced immune response to a tumor lysate vaccine and produced an elevated number of 













Slow-growing T-cell lymphomas are generally indolent, but in later stages, patients can 
develop serious complications and there is no cure. Fast-growing T-cell lymphomas have a 
poor prognosis. For this reason, the discovery of new immune therapies not only can reduce 
doses of standard therapy but also it can kill remaining tumor cells. Some of them, like 
monoclonal antibodies, have achieved moderate efficacy [47]. Thus, the search for more 
effective treatments is needed. In this regard, we conclude that imiquimod could represent a 
promising adjuvant to be employed in antitumor vaccines for lymphomas, allowing the 
design of feasible immunization strategies, like tumor cell lysate vaccines, which usually 
are safe, inexpensive and easy to produce at large scale. These strategies could be carried 
out in combination with the standard therapy, not only to achieve an initial complete 
response, but also to prevent relapses through the induction of immunological memory. 
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Figure 1: Imiquimod enhanced the protective antitumor response elicited by the LBC-
lysate vaccine. A) Mice were i.p. injected twice with either LBC-lysate with or without 
100 μg of imiquimod, LBC.CD40-lysate with or without 100 μg of imiquimod, or PBS 
alone or with 100 μg of imiquimod as control groups. Seven days after the last 
immunization mice received an i.p. tumor challenge with 1x10
6
 viable LBC cells and 
subsequently followed up for survival. The graph depicts a standard Kaplan-Meier survival 
curve analyzed by means of log-rank test. *, p<0.05. Ns, non-significant, (n=12-15). B) 
Mice previously immunized with LBC-lysate, alone or with 100 μg of imiquimod that had 
rejected first tumor challenge were i.p. injected with 1x10
6
 tumor LBC cells. The control 
group was made up of naïve animals of the same age that were i.p. inoculated with 1x10
6
 
tumor LBC cells at the time of challenge. Survival was monitored and data were analyzed 
by log-rank test. *, p<0.05 with respect to naïve control group. Ns, non-significant, (n=5). 
Data from two independent experiments are shown. 
 
Figure 2: Analysis of CD4+ and CD8+ T-cells and B220+ B-cells elicited by the LBC-
lysate + imiquimod vaccine. Freshly isolated peritoneal cells (A) and freshly isolated 
spleen cells (B); or spleen cells in vitro re-stimulated for 7 days with irradiated LBC cells 
(C) were obtained from mice that had rejected LBC tumor and that received PBS, 
imiquimod alone or LBC-lysate with or without imiquimod (imq). Frequencies and cell 
number of the different populations were evaluated by flow cytometry. Graphs show 












post-test, n=3). Bars represent mean ± standard deviation. Data presented are from two 
independent experiments. 
 
Figure 3: Th1/Th2-cytokine profile and specific cytotoxic response generated by 
combination of the LBC-lysate with imiquimod. Splenocytes (A, C) and peritoneal cells 
(B) isolated from mice injected with PBS or immunized with LBC-lysate with or without 
imiquimod (imq) that had rejected tumor challenge were re-stimulated in vitro for 48 h with 
irradiated LBC cells and the secretion of IFN-γ and IL-4 was determined in cell culture 
supernatants by ELISA. **, p<0.01. ***, p<0.001. Ns, non-significant (One way ANOVA 
and Tukey’s post-test, n=4). D) Specific cytotoxic activity of splenocytes from mice that 
received PBS or LBC-lysate with or without imiquimod that survived tumor injection, 
tested by the Jam test. The optimum effector/target ratio of 90:1 has previously been 
determined. ***, p<0.001 respect to normal control group (One way ANOVA and Tukey’s 
post-test, n=4). Data represent mean ± standard deviation and are from two independent 
experiments. 
 
Figure 4: The addition of imiquimod to the LBC-lysate vaccine induced a humoral 
immune response. Sera from mice that received PBS or LBC-lysate, alone or with 
imiquimod (imq) and had rejected tumor challenge were collected and incubated with 
1x10
4
 LBC cells. Sera from naïve mice were used as control. The antibody titer was 
determined by Dot Blot as the inverse of the last dilution that was positive (indicated by 
arrows). Data presented are from one experiment that is representative of two independent 




































































1) Imiquimod displayed adjuvant properties of a murine T-lymphoma-lysate vaccine 
2) Imiquimod enhanced CD4+T-cell and IFN-γ production induced by a tumor lysate 
vaccine 
3) Imiquimod as adjuvant of a tumor-lysate vaccine induced high T-cell lymphoma 
rejection 
4) Administration of imiquimod by systemic route was effective and no toxic  
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